Skip to main content
Premium Trial:

Request an Annual Quote

DermTech Partners With Stanford School of Medicine to Study Chronic Skin Disorder

NEW YORK — Molecular diagnostics firm DermTech said on Tuesday that it will work with researchers from the Stanford University School of Medicine to investigate biomarkers of the chronic skin disorder hidradenitis suppurativa.

HS, also known as acne inversa, is characterized by recurrent swollen and painful lesions in the armpit, groin, anal, and breast regions, according to DermTech. The primary etiology of the condition is poorly defined, and it can take years to diagnose properly.

Over the course of a three-year study, DermTech and university investigators will use the company's noninvasive sample collection and genomics technologies to identify and longitudinally evaluate biomarkers in HS patients. The goal of the study is to phenotypically characterize HS, identify potential subsets of the disease, and gain insights that can help guide treatment decisions.

"We are excited to collaborate with the team at Stanford to longitudinally evaluate biomarkers that are associated with disease flares in HS and are committed to improving our understanding of HS as we strive to use precision and personalized dermatology approaches to positively impact those suffering from the disease," DermTech CSO Michael Howell said in a statement.

In March, La Jolla, California-based DermTech reported a 31 percent rise in fourth quarter revenues on strong sales of its melanoma detection tests.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more